Location of Repository

Modulation of airway inflammation in COPD

By Roshan Siva

Abstract

COPD is a preventable, treatable, slowly progressive condition, associated with an\ud abnormally amplified inflammatory response, characterised by an accelerated decline in lung function, punctuated by exacerbations. Exacerbations cause considerable mortality, morbidity, and cost. Airway inflammation in COPD is mainly neutrophilic although eosinophilic airway inflammation plays an important role, particularly during exacerbations. Inflammation in foregut derivatives outside the lung may contribute to amplification of airway inflammation. I have shown that a management strategy aiming to minimise eosinophilic airway inflammation as well as symptoms is associated with a significant 62% reduction in the frequency of severe exacerbations of COPD. This strategy was associated with no overall increase in corticosteroid treatment; there was evidence that increased corticosteroid therapy was targeted to patients with eosinophilic airway inflammation and benefit was largely confined to these patients.\ud I have shown an association between the sputum differential neutrophil count and\ud airway bacterial load, and showed that a one week course of Levofloxacin\ud significantly reduced both the % neutrophil count and bacterial load in patients with\ud stable state COPD and bacterial load > 10^6 cfu/ml. I have shown that the prevalence\ud of peptic ulcer disease increases progressively with increasing severity of COPD in\ud miners with homogeneous risk factors for development of COPD, and that peptic\ud ulceration was a strong and independent predictor of a low FEV_1% predicted and\ud FEV_1\bigFVC ratio. In another population I showed that H. Pylori seropositivity was\ud more common in patients with COPD compared to healthy smokers matched for age\ud and occupation.\ud We have shown that TREM-1 can be measured from induced sputum and is\ud potentially a novel marker of bacterial infection and neutrophilic airway inflammation\ud during exacerbations.\ud Further work is required to ensure that measurement and modulation inflammation of airway results in improved clinical outcomes, and is made more clinically\ud viable

Publisher: University of Leicester
Year: 2006
OAI identifier: oai:lra.le.ac.uk:2381/4732

Suggested articles

Preview

Citations

  1. (1995). A et al. Bacterial infection in COPD; a study of stable and exacerbated outpatients using the protected specimen brush. doi
  2. (2002). A long term evaluation of once daily inhaled Tiotropium in COPD. doi
  3. (1987). A measure of quality of life for clinical trials in chronic lung disease. Thorax doi
  4. A S. The association of diffuse obstructive pulmonary emphysema and chronic gastroduodenal ulceration. doi
  5. Accelerated decline of lung function in COPD patients with chronic Hepatitis C virus infection. doi
  6. (1958). Acute peptic ulceration in chronic emphysema. Lancet doi
  7. (2003). Airway bacterial load and FEV 1 decline in patients with COPD. doi
  8. (1994). Airway eosinophilia in chronic bronchitis during exacerbations. doi
  9. Airway function and markers of airway inflammation in patients with treated hypothyroidism.
  10. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. doi
  11. (1996). Airways obstruction, chronic expectoration, and rapid decline in FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax doi
  12. (2005). Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Resp J doi
  13. and committee members. Standards for the diagnosis and treatment of patients with COPD.
  14. Antibiotic therapy in exacerbations of COPD.
  15. (2000). Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. doi
  16. (2002). Asthma exacerbations and sputum eosinophil counts. A randomised control trial: Lancet doi
  17. (2005). Bradding P: Sputum eosinophilia and the short term response to inhaled Mometasone in COPD. Thorax
  18. Bronchial inflammation; its relationship to colonising microbial load and alpha-1-antitrypsin deficiency.
  19. BTS guidelines for the management of COPD. The COPD guidelines group of the standards of care committee. Thorax 1997; 52 (suppl v): doi
  20. Burden and clinical features of chronic obstructive pulmonary disease. doi
  21. case of cough, lymphocytic bronchioalveolitis and coeliac disease with improvement following a gluten free diet. doi
  22. (1999). CD8+ cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med doi
  23. (1998). CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med doi
  24. changes in bronchial inflammation during acute exacerbations of chronic bronchitis. doi
  25. (1995). Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax doi
  26. (2002). Chronic obstructive pulmonary disease surveillance - United States 1971-2000. MMWR
  27. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. doi
  28. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. doi
  29. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. doi
  30. (2005). Correlation of sputum bacteriology with laboratory parameters, Anthonisens criteria and lung function in acute exacerbations of chronic obstructive pulmonary disease.
  31. (2005). Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004.363: 731-Barnes P J. New approaches to COPD. Eur Respir Rev doi
  32. (1992). Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis doi
  33. (1994). Corticosteroids contribute to muscle weakness in chronic airflow obstruction. doi
  34. Crit care doi
  35. (2000). Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. doi
  36. development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma. doi
  37. (2003). Disease severity and the effect of fluticasone proprionate on COPD exacerbations. Eur Resp J doi
  38. (2000). double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe COPD: the ISOLDE trial. BMJ doi
  39. (1984). Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state. Thorax doi
  40. (2002). Effect of discontinuation of inhaled corticosteroids in patients with COPD; the COPE study. doi
  41. (1998). Effect of exacerbation on quality of life in patients with COPD. Am J Respir Crit Care Med doi
  42. (2004). Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet doi
  43. (2000). Effects of an IL-5 blocking monoclonal antibody on eosinophilic airway hyper-responsiveness and the late asthmatic response. Lancet doi
  44. (1999). Efficacy of Salmeterol xinafoate in the treatment of COPD. Chest doi
  45. (1993). Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. doi
  46. (2002). European respiratory society/ European lung foundation. Preliminary data from the European white book on lung disease,
  47. (1998). Exhaled nitric oxide in chronic obstructive pulmonary disease. doi
  48. (2004). for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax doi
  49. (2004). Genetic epidemiology of COPD. Chest 2002.121: 1 s-6s doi
  50. (2001). Global strategy for the diagnosis, management and prevention of COPD. doi
  51. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. doi
  52. Helicobacter pylori secretes chemotactic factor for monocytes and neutrophils. doi
  53. (1993). High serum procalcitonin concentrations in patients with sepsis and infection. Lancet doi
  54. Idiopathic chronic cough: association with organ specific autoimmune disease and bronchoalveolar lymphocytosis. doi
  55. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. doi
  56. (2001). Induced sputum and other outcome measures in COPD- Safety and repeatability. Resp med. doi
  57. (1998). Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with Chronic Obstructive Pulmonary Disease. Thorax doi
  58. Lindqvist A E, Laitinen L A. Safety of sputum induction in chronic obstructive pulmonary disease. doi
  59. Long-term effect of inhaled Budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. doi
  60. (1997). Lopez A D. Alternative projections of mortality and disability by cause. Lancet doi
  61. (1984). Lung disease in long term cigarette smokers with and without chronic airflow obstruction. Am Rev Respir Dis
  62. (2001). Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J doi
  63. (1998). Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ doi
  64. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction?
  65. (2005). Modulation of eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. doi
  66. (1994). Morphological and cellular basis for airflow limitation in smokers. doi
  67. (1980). Morphological and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis
  68. (1998). Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with COPD: Lancet doi
  69. Neopterin as a marker for activated cellmediated immunity. Application in HIV infection. doi
  70. Neopterin as a marker for activation of cellular immunity. Immunologic basis and clinical application. doi
  71. (1999). Non-eosinophilic corticosteroid unresponsive asthma. Lancet doi
  72. on behalf of the ISOLDE study group. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. doi
  73. Once daily oral Ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. doi
  74. Ongoing airway inflammation in patients with COPD who do not currently smoke. doi
  75. (2000). Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. doi
  76. (2001). Pathogenesis and pathology of COPD. Respiration doi
  77. Pathophysiology of airflow limitation in COPD. doi
  78. (1995). Procalcitonin; a new marker of host inflammatory response. Longitudinal studies in patients with sepsis and peritonitis. Chir gastroenterol doi
  79. Pylori seroprevalence in patients with chronic bronchitis. doi
  80. (2002). Relationship between exacerbation frequency and lung function decline in COPD. Thorax doi
  81. (2003). Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax doi
  82. (1998). Respir Crit Care Med doi
  83. Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease.
  84. (2002). Role of newer fluoroquinolones in lower respiratory tract infections. doi
  85. (2003). Salmeterol/Fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. Lancet
  86. (1998). Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. doi
  87. (1995). Simple method for quantifying viable bacterial numbers in sputum. doi
  88. (2000). Sputum eosinophilia and short term response to prednisolone in COPD. A randomised control trial. Lancet doi
  89. Sputum eosinophilia predicts benefit from prednisolone in smokers with chronic obstructive bronchitis. doi
  90. the amplification of inflammation in emphysema and its association with latent adenoviral infection. doi
  91. The burden of H. Pylori infection in England and Wales. doi
  92. The lung in inflammatory bowel disease. doi
  93. The nature of small-airway obstruction in COPD. doi
  94. The New England doi
  95. The role of viral infections in patients admitted with acute exacerbations of COPD. Eur Respir i 2004. vol 24. supplement 48.408 s,
  96. (1992). The use of induced sputum to investigate airway inflammation. Thorax doi
  97. (2005). Treatment of stable COPD: antioxidants. Eur Respir Rev doi
  98. Triggering receptor expressed on myeloid cells : role in the diagnosis of lung infections. doi
  99. (2002). World health report doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.